Review | Published:

Endogenous cannabinoid system as a modulator of food intake

International Journal of Obesity volume 27, pages 289301 (2003) | Download Citation

This work was supported by a grant ‘Giovani Ricercatori’, University of Bologna and in part by Fondazione Cassa di Risparmio, Bologna, Italy.

Subjects

Abstract

The ability of Cannabis sativa (marijuana) to increase hunger has been noticed for centuries, although intensive research on its molecular mode of action started only after the characterization of its main psychoactive component Δ9-tetrahydrocannabinol in the late 1960s. Despite the public concern related to the abuse of marijuana and its derivatives, scientific studies have pointed to the therapeutic potentials of cannabinoid compounds and have highlighted their ability to stimulate appetite, especially for sweet and palatable food. Later, the discovery of specific receptors and their endogenous ligands (endocannabinoids) suggested the existence of an endogenous cannabinoid system, providing a physiological basis for biological effects induced by marijuana and other cannabinoids. Epidemiological reports describing the appetite-stimulating properties of cannabinoids and the recent insights into the molecular mechanisms underlying cannabinoid action have proposed a central role of the cannabinoid system in obesity. The aim of this review is to provide an extensive overview on the role of this neuromodulatory system in feeding behavior by summarizing the most relevant data obtained from human and animal studies and by elucidating the interactions of the cannabinoid system with the most important neuronal networks and metabolic pathways involved in the control of food intake. Finally, a critical evaluation of future potential therapeutical applications of cannabinoid antagonists in the therapy of obesity and eating disorders will be discussed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    , . Obesity. N Engl J Med 2002; 346: 591–602.

  2. 2.

    , , , , . Central nervous system control of food intake. Nature 2000; 404: 661–671.

  3. 3.

    . Marijuana as a medicine. Nature 1997; 386: 320.

  4. 4.

    , , , . Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521–528.

  5. 5.

    . Cannabis: effects on hunger and thirst. Behav Biol 1975; 15: 255–281.

  6. 6.

    , , , , . Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92: 377–387.

  7. 7.

    , . The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90: 45–60.

  8. 8.

    , . Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646.

  9. 9.

    , , , , . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561–564.

  10. 10.

    , , . Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65.

  11. 11.

    , , , , , , , , , , , . International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 2002; 54: 161–202.

  12. 12.

    , . Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565–572.

  13. 13.

    . The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315–348.

  14. 14.

    , , , , . Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780–5785.

  15. 15.

    , , , , , , , , , , , . The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530–534.

  16. 16.

    , , , , , , , , , , , , . Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401–404.

  17. 17.

    , , , , , , , , , . Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946–1949.

  18. 18.

    , , , , , , , , . Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48: 443–450.

  19. 19.

    , , , , , , , , , , , . Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996; 393: 231–235.

  20. 20.

    , , , . Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36: 3032–3034.

  21. 21.

    , , , , , , , , , . Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83–90.

  22. 22.

    , , , , , , , . 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89–97.

  23. 23.

    , , , , , , , . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662–3665.

  24. 24.

    , , . A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773–778.

  25. 25.

    , , , , , , . Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686–691.

  26. 26.

    , , , , , , , . Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819–10824.

  27. 27.

    , , , , , , . Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 1988; 44: 762–764.

  28. 28.

    , , . Classical and nonclassical cannabinoids: mechanism of action-brain binding. NIDA Res Monogr 1990; 96: 100–111.

  29. 29.

    , , , , , , , , , . SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240–244.

  30. 30.

    , , , , , , , . Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS Pharm Sci 1999; 1: E4.

  31. 31.

    , , , , , , , , , , , , , . SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644–650.

  32. 32.

    , , , , , . AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci 1998; 62: L109–L113.

  33. 33.

    , , , , , . Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277: 1094–1097.

  34. 34.

    , , , , . Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000; 483: 52–56.

  35. 35.

    , , , , , . UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 2002; 449: 99–103.

  36. 36.

    . Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 123–142.

  37. 37.

    , , , . Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998; 5: 432–446.

  38. 38.

    , , , , , , , , , , , . Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 2001; 86: 2687–2696.

  39. 39.

    , , , , , , . Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491–496.

  40. 40.

    , , , , . Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid. J Ocul Pharmacol Ther 2000; 16: 217–230.

  41. 41.

    , , , , , , , . Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000; 408: 96–101.

  42. 42.

    , , , . Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 2001; 423: 203–210.

  43. 43.

    , , , . The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem Biophys Res Commun 2001; 284: 363–368.

  44. 44.

    , , , . Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000; 108: 191–209.

  45. 45.

    , , , , . Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975; 55: 597–602.

  46. 46.

    , . Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002; 8: 547–550.

  47. 47.

    , , , , , . Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313–319.

  48. 48.

    , , , , , , . An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527–531.

  49. 49.

    , , , , , . Marihuana smoking in Panama. Mil Surg 1933; 73: 269–280.

  50. 50.

    . Marijuana intoxication common experiences. Nature 1970; 226: 701–704.

  51. 51.

    , . Marijuana use patterns. Br J Addict Alcohol Other Drugs 1970; 65 : 347–362.

  52. 52.

    . Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 1971; 12: 44–49.

  53. 53.

    . Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971; 231: 260–261.

  54. 54.

    , . Effects of marijuana and D-amphetamine on the appetite, food consumption and various cardio-respiratory variables in man. Union Med Can 1975; 104: 914–921.

  55. 55.

    , . The present position of hemp-drug addiction in India. Ind Med Res Mem 1939; 31: 1–119.

  56. 56.

    , , , . Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl) 1976; 49: 79–84.

  57. 57.

    , , . Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 1986; 25: 577–582.

  58. 58.

    , , . Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988; 11: 1–14.

  59. 59.

    , , , . Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994; 49: 187–195.

  60. 60.

    , . Endogenous cannabinoids and appetite. Nutr Res Rev 2001; 14: 65–86.

  61. 61.

    , . Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999; 143: 315–317.

  62. 62.

    . Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 2001; 68: 539–543.

  63. 63.

    . Cancer cachexia and cannabinoids. Forsch Komplementarmed 1999; 6 (Suppl 3): 21–22.

  64. 64.

    , , , , , , , , , , , . Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.J Pain Symptom Manage 1997; 14: 7–14.

  65. 65.

    . Cannabinoids and the control of chemotherapy-induced nausea and vomiting. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S (eds). Marihuana and medicine. Humana Press: Totowa, NJ; 1999. pp 599–610.

  66. 66.

    , , , , , . Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 1977; 39: 303–313.

  67. 67.

    , , . Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795–797.

  68. 68.

    , , , , , . Δ9-Tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Brande MC, Szara S (eds). The pharmacology of marijuana. Raven Press: New York; 1976. pp 763–776.

  69. 69.

    , , , , , . Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695–700.

  70. 70.

    , , . Dronabinol effects on weight in patients with HIV infection. AIDS 1992; 6: 127.

  71. 71.

    , , , , , , , . Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27: 827–831.

  72. 72.

    , , , , , , , , . Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89–97.

  73. 73.

    , , , , . Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 913–919.

  74. 74.

    , . Effects of Cannabis sativa (marihuana) on maze performance of the rat. Psychopharmacologia 1965; 7: 175–181.

  75. 75.

    , , . Some pharmacological and toxicological effects of 1-trans- 8 and 1-trans- 9 -tetrahydrocannabinol in laboratory rodents. Arch Int Pharmacodyn Ther 1972; 196: 133–145.

  76. 76.

    , , , . Oral and intravenous toxicity of delta9-tetrahydrocannabinol in rhesus monkeys. Toxicol Appl Pharmacol 1974; 27: 648–665.

  77. 77.

    , , , , . Inhibition of normal growth by chronic administration of delta-9-tetrahydrocannabinol. Science 1971; 174: 424–426.

  78. 78.

    , , . Influence of tetrahydrocannabinols (delta8-THC and delta9-THC) on body weight, food, and water intake in rats. Pharmacol Biochem Behav 1973; 1: 395–399.

  79. 79.

    , , , . Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 1974; 38: 329–338.

  80. 80.

    , . Acute and chronic effects of delta9-tetrahydrocannabinol on food intake by rats. Psychopharmacologia 1974; 39: 213–222.

  81. 81.

    , , . Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of delta9-tetrahydrocannabinol. Behav Biol 1977; 20: 104–110.

  82. 82.

    , , . Cannabinols and feeding in sheep. Psychopharmacology (Berl) 1979; 64: 321–323.

  83. 83.

    , , , . Feeding and depression of abomasal secretion in sheep elicited by elfazepam and 9-aza-cannabinol. Pharmacol Biochem Behav 1979; 11: 51–56.

  84. 84.

    , , . Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 1998; 65: 343–346.

  85. 85.

    , , . Oral and hypothalamic injections of barbiturates, benzodiazepines and cannabinoids and food intake in rats. Pharmacol Biochem Behav 1979; 11: 487–491.

  86. 86.

    , . Facilitory effect of delta 9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology (Berl) 1991; 103: 172–176.

  87. 87.

    , , , , , , . Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid CB1 receptors. Psychopharmacology (Berl) 1997; 132: 104–106.

  88. 88.

    , . The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716. Psychopharmacology (Berl) 1999; 142: 302–308.

  89. 89.

    , , , . Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 2001; 25: 277–282.

  90. 90.

    , , , . SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998; 9: 179–181.

  91. 91.

    , , , , , . Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: L113–L117.

  92. 92.

    , , . Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000; 67: 265–270.

  93. 93.

    , , , . Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392: 147–156.

  94. 94.

    , , , , , , , , , , . Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland. Neuroendocrinology 1999; 70: 137–145.

  95. 95.

    , . Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151–1154.

  96. 96.

    , , , , , , , , , , . Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822–825.

  97. 97.

    , . The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999; 22: 521–527.

  98. 98.

    , . Cannabinoid transmission and reward-related events. Neurobiol Dis 1998; 5: 502–533.

  99. 99.

    . Brain neurotransmitters in food and drug reward. Am J Clin Nutr 1985; 42: 1133–1150.

  100. 100.

    , . The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 1998; 5: 417–431.

  101. 101.

    , . Physiology. A hunger for cannabinoids. Nature 2001; 410: 763–765.

  102. 102.

    , . Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem Res 2001; 26: 1015–1021.

  103. 103.

    , , . Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415–421.

  104. 104.

    , , , . Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 1999; 370: 233–240.

  105. 105.

    , . Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13: 243–281.

  106. 106.

    , , , , , , . Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999; 256: 377–380.

  107. 107.

    , , . Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451–460.

  108. 108.

    , , . Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299–318.

  109. 109.

    . Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 1996; 20: 1–25.

  110. 110.

    , , , , , , , , . Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000; 74: 1627–1635.

  111. 111.

    , , . Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 2001; 41: 200–209.

  112. 112.

    , , . Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl) 2001; 159: 111–116.

  113. 113.

    , , , , , , , , , , , , . Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21: 5344–5350.

  114. 114.

    , . Opioid mechanisms in the control of food consumption and taste preferences. In: Herz A, Akil H, Simon EJ (eds.) Handbook of experimental pharmacology. Springer-Verlag: Berlin; 1993. pp 239–263.

  115. 115.

    , . Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 2001; 153: 267–270.

  116. 116.

    , . Reversal of Delta(9)-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002; 71: 333–340.

  117. 117.

    , . Biological actions of cholecystokinin. Peptides 1994; 15: 731–755.

  118. 118.

    , . Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999; 11: 4213–4225.

  119. 119.

    , , , , . Cholecystokinin/opioid interactions. Brain Res 1999; 848: 78–89.

  120. 120.

    , . Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci Lett 2001; 301: 69–71.

  121. 121.

    , , , , , , , , , , , , . An anorexic lipid mediator regulated by feeding. Nature 2001; 414: 209–212.

  122. 122.

    , , , , , , . Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322–328.

  123. 123.

    , . Hypothalamic peptides as drug targets for obesity. Curr Opin Pharmacol 2001; 1: 651–655.

Download references

Author information

Affiliations

  1. Neuroendocrinology Group, Max-Planck-Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany

    • D Cota
    •  & G K Stalla
  2. Molecular Genetics of Behaviour Group, Max-Planck-Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany

    • G Marsicano
    •  & B Lutz
  3. Endocrinology Unit, Department of Internal Medicine and Gastroenterology, Center for Applied Biomedical Researches (C.R.B.A.) S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy

    • V Vicennati
    • , R Pasquali
    •  & U Pagotto

Authors

  1. Search for D Cota in:

  2. Search for G Marsicano in:

  3. Search for B Lutz in:

  4. Search for V Vicennati in:

  5. Search for G K Stalla in:

  6. Search for R Pasquali in:

  7. Search for U Pagotto in:

Corresponding author

Correspondence to U Pagotto.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/sj.ijo.0802250